GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avadel Pharmaceuticals PLC (STU:AWK) » Definitions » Forward PE Ratio

Avadel Pharmaceuticals (STU:AWK) Forward PE Ratio : 0.00 (As of Jun. 07, 2024)


View and export this data going back to 2024. Start your Free Trial

What is Avadel Pharmaceuticals Forward PE Ratio?

Avadel Pharmaceuticals's Forward PE Ratio for today is 0.00.

Avadel Pharmaceuticals's PE Ratio without NRI for today is 0.00.

Avadel Pharmaceuticals's PE Ratio for today is 0.00.


Avadel Pharmaceuticals Forward PE Ratio Historical Data

The historical data trend for Avadel Pharmaceuticals's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avadel Pharmaceuticals Forward PE Ratio Chart

Avadel Pharmaceuticals Annual Data
Trend 2015-12 2016-12 2017-09
Forward PE Ratio
14.53 49.26 88.50

Avadel Pharmaceuticals Quarterly Data
2015-12 2016-03 2016-06 2016-09 2016-12 2017-03
Forward PE Ratio 14.53 18.21 119.05 18.76 49.26 38.91

Competitive Comparison of Avadel Pharmaceuticals's Forward PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Avadel Pharmaceuticals's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avadel Pharmaceuticals's Forward PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Avadel Pharmaceuticals's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Avadel Pharmaceuticals's Forward PE Ratio falls into.



Avadel Pharmaceuticals Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Avadel Pharmaceuticals  (STU:AWK) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Avadel Pharmaceuticals Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Avadel Pharmaceuticals's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Avadel Pharmaceuticals (STU:AWK) Business Description

Traded in Other Exchanges
Address
10 Earlsfort Terrace, Dublin 2, Dublin, IRL, D02 T380
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company markets products in both the primary care and sterile injectables markets. Its products portfolio includes Bloxiverz, Vazculep (phenylephrine hydrochloride injection), Akovaz (ephedrine sulfate injection), Karbinal ER (carbinoxamine maleate extended-release oral suspension), AcipHex Sprinkle (rabeprazole sodium), Cefaclor for Oral Suspension, 125 mg/5 mL, 250 mg/5 mL and 375 mg/5 mL, and Flexichamber. Majority of the revenue is derived from the United States.